Updated branding gives J&J 2 segments sharing 1 name

A healthcare logo familiar to Americans since the 1800s has gotten a makeover.

Johnson & Johnson says it’s scrapping the historic visual identity—which was adapted from the signature of company founder Robert Wood Johnson (1845-1910)—in favor of a modernized version. (See photo.)

In the new typography, the company explains in a Sept. 14 announcement, “each letter is drawn in one pen stroke, creating a contrast that delivers both a sense of unexpectedness and humanity.”

The logo refresh is only part of the story.

The company is re-badging Janssen, its pharma business, as Johnson & Johnson Innovative Medicine.

Its medical technology segment will continue to identify as Johnson & Johnson MedTech. 

The company says it’s making the changes while reinforcing the common name to “demonstrate [our] collective power in healthcare.”

“Our Johnson & Johnson brand identity communicates our bold approach to innovation in healthcare while staying true to the care we have for our patients around the world,” adds J&J’s executive VP of global corporate affairs, Vanessa Broadhurst. “We take immense pride in leading healthcare for more than a century and are seizing on our scientific momentum to profoundly impact health for humanity.”

Full announcement here.

 

Dave Pearson

Dave P. has worked in journalism, marketing and public relations for more than 30 years, frequently concentrating on hospitals, healthcare technology and Catholic communications. He has also specialized in fundraising communications, ghostwriting for CEOs of local, national and global charities, nonprofits and foundations.

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.